> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Info Collection Revision on Biosimilar Program
- URL: https://www.fdaweb.com/info-collection-revision-on-biosimilar-program/
- Published: 2019-11-22T12:00:00.000Z
- Updated: 2026-09-14T15:54:06.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5145572

*Federal Register* notice: FDA is seeking comments on an information collection extension for “General Licensing Provisions; Section 351(k) Biosimilar Applications; Formal Meetings Between the FDA and Sponsors or Applicants” (OMB Control Number 0910–0719). The revision is related to certain performance goals under the FDA Reauthorization Act of 2017 and its Biosimilar User Fee program. The goals are found [here](https://www.fda.gov/media/%20100573/download?ref=fdaweb.com). To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-11-22/pdf/2019-25328.pdf?ref=fdaweb.com).